Description
Anti-PCSK9 Antibody, ADCC Enchanced (BioBet-CB-082LX) is a glycosylation-modified anti-PCSK9 therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced PCSK9 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
PCSK9
Full Name
Proprotein convertase subtilisin/kexin type 9
Background
This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]
Alternative Names
PCSK9; Proprotein convertase subtilisin/kexin type 9; FH3; PC9; FHCL3; NARC1; LDLCQ1; NARC-1; HCHOLA3
Gene ID
255738
UniProt ID
Q8NBP7
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG2
Antibody Clone
BioBet-CB-082LX
Description
ADCC-Enhanced Anti-Human PCSK9 (Tafolecimab) Antibody is derived from clone Tafolecimab, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the PCSK9, and it is intended for the research of Heterozygous familial hypercholesterolemia .
Antibody Indication
Heterozygous familial hypercholesterolemia
Heterozygous familial hypercholesterolemia
